Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes.
Journal: 2006/November - Endocrinology and Metabolism Clinics of North America
ISSN: 0889-8529
Abstract:
Both type 1 and type 2 diabetes melitius are associated with increased cardiovascular morbidity, and now affect more than 170 million individuals worldwide. The incidence of type 2 diabetes is growing rapidly and now accounts for 90 to 95 percent of all diabetes cases. Thiazolidinediones (TZDs) a class of insulin sensitizing agents commonly used in the treatment of patients who have type 2 diabetes, improve endothelial dysfunction and exert beneficial effects on lipid profiles by activating the nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR-gamma). In addition, TZDs exhibit antiatherogenic effects, independent of their antidiabetic and lipid-lowering properties, by attenuating proinflammatory processes. The combination of increased insulin sensitivity, improved lipid profile, and reduced inflammation may explain the cardiovascular benefits of this class of drugs
Relations:
Citations
(6)
Diseases
(6)
Conditions
(2)
Chemicals
(3)
Organisms
(2)
Affiliates
(1)
Similar articles
Articles by the same authors
Discussion board
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.